Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Diabete Mellitus: later-stage trial registry

3 of 7 indexed Diabete Mellitus trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Diabete Mellitus: 7 US clinical trials tracked, 3 recruiting.

Diabete Mellitus is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Abbott Diabetes Care, running 3 of these trials.

Enrollment posture brief

Registry condition diabete-mellitus

OPEN 3 | RECR 43% | LATE 1 | EARLY 0 | RANK #2497 | SPON 3

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Diabete Mellitus (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Diabete Mellitus

Diabete Mellitus lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabete Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabete Mellitus is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Diabete Mellitus research.

    Abbott Diabetes Care accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabete Mellitus enrolment sits around 80 participants.

    Median target enrolment is 80 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Diabete Mellitus splits between interventional and observational designs.

    3 interventional and 4 observational studies make up this index (42.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Top Sponsors

Nova Biomedical 1 trials
BioXTek 1 trials
Senseonics 1 trials

Named interventions

Most-linked intervention names on Diabete Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Device: FreeStyle Libre Flash Glucose Monitoring System Device
1 trials
FreeStyle Libre Device
1 trials
Glucose, Creatinine Diagnostic test
1 trials
Placental Membrane Biological
1 trials
FreeStyle Libre 2 Device
1 trials
Continuous Glucose Monitoring System Device
1 trials

US sites by state

Facility locations filed on Diabete Mellitus trials. A trial with sites in several states counts in each.

California 3 trials
Washington 2 trials
Texas 2 trials
Idaho 2 trials
New York 1 trials
Nevada 1 trials
Missouri 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabete Mellitus page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabete Mellitus condition card totals 7 registered trials; most-linked intervention Device: FreeStyle Libre Flash Glucose Monitoring System; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.